NCT00834353

Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis

Prospective Study of N-acetyltransferase2 (NAT2) Gene and Rifampicin Induced Cytochrome P-450 as Susceptible Risk Factors for Antituberculosis Drug Induced Hepatitis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: —
• Sponsor: Maulana Azad Medical College · Academic / Other
• Sex: All
• Age: 10 Years – 70 Years
• Healthy volunteers: Accepted

Summary

N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) are two drug metabolizing enzymes. Antituberculosis drug isoniazid is acetylated by NAT2 and forms ultimately a nontoxic compound which is metabolized by CYP2E1 to a toxic metabolite. Slow acetylator genotype of NAT2 and wild type genotype of CYP2E1 gene has been attributed to greater toxicity of ATT drug. Therefore this study has been designed to analyze the genetic polymorphism of NAT2 and CYP2E1 genes in tuberculosis patients who developed drug induced hepatitis upon administration of antituberculosis drug.Polymorphism study of NAT2 and CYP2E1 gene may help in predicting the high risk group of ATT induced hepatitis.

Conditions

• Pulmonary Tuberculosis

Interventions

Type	Name	Description
DRUG	ATT

Timeline

• Start date: 2005-09-01
• Primary completion: 2008-03-01
• Completion: 2008-09-01
• First posted: 2009-02-03
• Last updated: 2009-02-03

Locations

1 site across 1 country: India